Clinical perspectives in drug safety and adverse drug reactions

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Expert Review of Clinical Pharmacology

• Publication date

  2008-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1586/17512433.1.5.695PMID 24422739
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacogenomic biomarkers for prediction of severe adverse drug reactions.

  2008cited by this paper
• Protecting Health

  2008cited by this paper
• A European study of HLA-B in Stevens–Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs

  2008cited by this paper
• What have we learnt from Vioxx?

  2007cited by this paper
• Tamiflu and neuropsychiatric disturbance in adolescents

  2007cited by this paper
• Evaluating medicines: let's use all the evidence

  2007cited by this paper
• The role of litigation in defining drug risks.

  2007cited by this paper
• Men's health

  2007cited by this paper
• Bolstering the FDA's drug-safety authority.

  2007cited by this paper
• Widespread Hyoscine Hydrobromide Toxicity Due to Contract Manufacturer Malpractice

  2007cited by this paper
• Use of Triage Strategies in the WHO Signal-Detection Process

  2007cited by this paper
• Blueprint for a stronger Food and Drug Administration.

  2006cited by this paper
• Outpatient gatifloxacin therapy and dysglycemia in older adults.

  2006cited by this paper
• IOM: overhaul drug safety monitoring.

  2006cited by this paper
• Reform of drug regulation--beyond an independent drug-safety board.

  2006cited by this paper
• Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study.

  2006cited by this paper
• The FDA and drug safety: a proposal for sweeping changes.

  2006cited by this paper
• Protecting the health of the public--Institute of Medicine recommendations on drug safety.

  2006cited by this paper
• Represcription after adverse drug reaction in the elderly: a descriptive study.

  2006cited by this paper
• Serious adverse drug effects--seeing the trees through the forest.

  2006cited by this paper
• Adverse drug events in general practice patients in Australia

  2006cited by this paper
• Risk management planning: time to deliver

  2006cited by this paper
• Under-Reporting of Adverse Drug Reactions

  2006cited by this paper
• Is there still a role for spontaneous reporting of adverse drug reactions?

  2006cited by this paper
• Australian Government

  2006cited by this paper
• Adverse Drug Reactions in United States Hospitals

  2006cited by this paper
• Brief Communication: Better Ways To Question Patients about Adverse Medical Events

  2006cited by this paper
• COX-2 inhibitors, other NSAIDs, and cardiovascular risk: the seduction of common sense.

  2006cited by this paper
• An educational intervention to improve physician reporting of adverse drug reactions: a cluster-randomized controlled trial.

  2006cited by this paper
• A call for international harmonization in therapeutic risk management

  2006cited by this paper
• How the US drug safety system should be changed.

  2006cited by this paper
• Ambulatory care visits for treating adverse drug effects in the United States, 1995-2001.

  2005cited by this paper
• Physicians’ Attitudes and Adverse Drug Reaction Reporting

  2005cited by this paper
• Drug safety. Gaps in the safety net.

  2005cited by this paper
• Drug withdrawals from the Canadian market for safety reasons, 1963–2004

  2005cited by this paper
• Adverse Drug Reaction Reporting: Attitudes of Australian Hospital Pharmacists and Doctors

  2005cited by this paper
• Gaps in the Safety Net

  2005cited by this paper
• Adverse drug reactions in older Australians, 1981–2002

  2005cited by this paper
• Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.

  2005cited by this paper
• Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.

  2005cited by this paper
• Cyclooxygenases, Thromboxane, and Atherosclerosis: Plaque Destabilization by Cyclooxygenase-2 Inhibition Combined With Thromboxane Receptor Antagonism

  2005cited by this paper
• Impact Analysis of Signals Detected from Spontaneous Adverse Drug Reaction Reporting Data

  2005cited by this paper
• Adverse drug reaction teaching in UK undergraduate medical and pharmacy programmes

  2004cited by this paper
• Merck's recall of rofecoxib--a strategic perspective.

  2004cited by this paper
• A marker for Stevens–Johnson syndrome

  2004cited by this paper
• A coxib a day won't keep the doctor away.

  2004cited by this paper
• Risk of cardiovascular events and rofecoxib: cumulative meta-analysis.

  2004cited by this paper
• Postmarketing surveillance--lack of vigilance, lack of trust.

  2004cited by this paper
• Clinical judgment, common sense and adverse reaction reporting

  2004cited by this paper
• Coxibs and cardiovascular disease.

  2004cited by this paper
• Pure red-cell aplasia and epoetin therapy.

  2004cited by this paper
• Expecting the unexpected--drug safety, pharmacovigilance, and the prepared mind.

  2004cited by this paper
• Failing the public health--rofecoxib, Merck, and the FDA.

  2004cited by this paper
• Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients

  2004cited by this paper
• Better Reporting of Harms in Randomized Trials: An Extension of the CONSORT Statement

  2004cited by this paper
• Incidence of idiopathic acute liver failure and hospitalized liver injury in patients treated with troglitazone.

  2003cited by this paper
• A model for the future conduct of pharmacovigilance

  2003cited by this paper
• Incidence of Idiopathic Acute Liver Failure and Hospitalized Liver Injury in Patients Treated With Troglitazone

  2003cited by this paper
• Under-reporting of adverse drug reactions in general practice.

  2003cited by this paper
• Joining the DoTS: new approach to classifying adverse drug reactions

  2003cited by this paper
• Adverse drug reactions: back to the future.

  2003cited by this paper
• Population-based studies of adverse drug effects.

  2003cited by this paper
• Reporting of adverse drug reactions by hospital doctors and the response to intervention.

  2003cited by this paper
• Preventable Drug-Related Hospital Admissions

  2002cited by this paper
• A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions

  2002cited by this paper
• DESIGN AND REPORTING MODIFICATIONS IN INDUSTRY-SPONSORED COMPARATIVE PSYCHOPHARMACOLOGY TRIALS

  2002cited by this paper
• Timing of new black box warnings and withdrawals for prescription medications.

  2002cited by this paper
• Physicians' knowledge and attitudes regarding the spontaneous reporting system for adverse drug reactions.

  2002cited by this paper
• The role of the Australian Adverse Drug Reactions Advisory Committee (ADRAC) in monitoring drug safety.

  2002cited by this paper
• Cerivastatin and reports of fatal rhabdomyolysis.

  2002cited by this paper
• Importance of emergency identification schemes

  2002cited by this paper
• Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and food and drug administration regulatory actions

  2001cited by this paper
• The Revised CONSORT Statement for Reporting Randomized Trials: Explanation and Elaboration

  2001cited by this paper
• The management of adverse drug reactions: from diagnosis to signal.

  2001cited by this paper
• Prescription-event monitoring and reporting of adverse drug reactions.

  2001cited by this paper
• Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports

  2001cited by this paper
• Attitudes and knowledge of hospital pharmacists to adverse drug reaction reporting.

  2001cited by this paper
• Risk of cardiovascular events associated with selective COX-2 inhibitors.

  2001cited by this paper
• Troglitazone (Rezulin) and hepatic injury

  2001cited by this paper
• Evaluation of the Characteristics of Safety Withdrawal of Prescription Drugs from Worldwide Pharmaceutical Markets-1960 to 1999

  2001cited by this paper
• Attitudes to reporting adverse drug reactions in northern Sweden

  2000cited by this paper
• Admissions to hospital caused by adverse drug reactions: cross sectional incidence study

  2000cited by this paper
• Admissions to hospital caused by adverse drug reactions: cross sectional incidence study. French Pharmacovigilance Centres.

  2000cited by this paper
• Adverse drug reactions: definitions, diagnosis, and management.

  2000cited by this paper
• Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.

  2000cited by this paper
• Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2.

  1999cited by this paper
• Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.

  1999cited by this paper
• COX-2 inhibitors.

  1999cited by this paper
• The MedWatch Program.

  1999cited by this paper
• Underreporting of Adverse Drug Reactions: Attitudes of Irish doctors

  1999cited by this paper
• The safety of newly approved medicines: do recent market removals mean there is a problem?

  1999cited by this paper
• Counting the Costs of Drug-Related Adverse Events

  1999cited by this paper
• Pharmacovigilance in Australia and New Zealand: towards 2000

  1999cited by this paper
• The New Zealand intensive medicines monitoring programme

  1998cited by this paper
• Fortnightly review: Adverse drug reactions

  1998cited by this paper
• The FDA and drug safety.

  1998cited by this paper
• The Role of the WHO Programme on International Drug Monitoring in Coordinating Worldwide Drug Safety Efforts

  1998cited by this paper
• MedWatch program.

  1998cited by this paper
• Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies.

  1998cited by this paper
• Underreporting of suspected adverse drug reactions to newly marketed (“black triangle”) drugs in general practice: observational study

  1998cited by this paper

• Effect of educational intervention on intern physician’s knowledge and attitude towards pharmacovigilance in selected tertiary hospitals of Bangladesh

  2024cites this paper
• Understanding NSAID-Induced Skin Reactions: Implications for Patient Care

  2024cites this paper
• Real-world reporting rates of administration-site reactions with on-demand treatment of hereditary angioedema attacks.

  2023cites this paper
• The evaluation of adverse drug reactions in Saudi Arabia: A retrospective observational study

  2022cites this paper
• Artificial Intelligence in Pharmacovigilance and Covid-19.

  2022cites this paper
• Adverse reactions to radiopharmaceuticals.

  2021cites this paper
• Overview of drug induced liver injury in Brazil: What is the role of public health policy on the evidence?

  2021cites this paper
• Overview of drug induced liver injury in Brazil: What is the role of public health policy on the evidence?

  2021cites this paper
• Pharmacovigilance

  2021cites this paper
• Stimulated adverse drug reaction reporting in pharmacovigilance: Indian perspectives

  2021cites this paper
• Adverse drug reactions with oral anticoagulants: data from sicilian spontaneous reporting system database

  2021cites this paper
• A population-based study of self-reported adverse drug events among Lebanese outpatients

  2021cites this paper
• Outcomes of adverse drug events reported with potentially inappropriate medications in older adults, 2004–2017

  2021cites this paper
• Features of International and Regional Pharmacovigilance Systems

  2020cites this paper
• Effectiveness of interventions to improve adverse drug reaction reporting by healthcare professionals over the last decade: A systematic review

  2019cites this paper
• Safety-Related Quality Issues for the Development of Herbal Drugs

  2019cites this paper
• Intensive monitoring of adverse drug reactions in nephrology unit of tertiary care teaching hospital

  2019cites this paper
• Anticoagulant-associated adverse drug reactions in 2013–15

  2018cites this paper
• Under-reporting of Adverse Drug Reactions to the Food & Drug Administration

  2018influential citation
• Methods to Compare Adverse Events in Twitter to FAERS, Drug Information Databases, and Systematic Reviews: Proof of Concept with Adalimumab

  2018cites this paper
• Addressing the under-reporting of adverse drug reactions in public health programs controlling HIV/AIDS, Tuberculosis and Malaria: A prospective cohort study

  2018cites this paper
• Biomarkers of adverse drug reactions

  2018cites this paper
• Pharmacodynamics—A Pharmacognosy Perspective

  2017cites this paper
• In-depth analysis of factors affecting variability in thiopurine methyltransferase activity

  2017cites this paper
• The key role of clinical and community health nurses in pharmacovigilance

  2017cites this paper
• Innovative Digital Tools and Surveillance Systems for the Timely Detection of Adverse Events at the Point of Care: A Proof-of-Concept Study

  2016cites this paper
• Adverse Drug Reactions: Definitions, Classifications and Regulatory Aspects

  2016cites this paper
• Dilemmas of the causality assessment tools in the diagnosis of adverse drug reactions

  2015cites this paper
• Pitfalls and Limitations of SPECT, PET, and Therapeutic Radiopharmaceuticals.

  2015cites this paper
• A Review of Pharmacovigilance.

  2015cites this paper
• Advances in the Pharmacogenomics of Adverse Drug Reactions

  2015cites this paper
• ADVERSE DRUG EVENTS - WHY WE CARE

  2015cites this paper
• Extent of Under Reporting of Adverse Drug Reactions (ADRs) in India: Evaluation using Logistic Regression Analysis (LRA) Model

  2014cites this paper
• Notificadores espontâneos de reacções adversas a medicamentos: estudo dos motivadores em farmacêuticos e médicos

  2011cites this paper
• An observational cohort study of extended dosing (once every 2 weeks or once monthly) regimens with darbepoetin alfa in patients with chronic kidney disease not on dialysis: the EXTEND study

  2011cites this paper
• Non-conventional hormone therapy - Tissue-specific Tibolone-Caution

  2010cites this paper
• Adverse Drug Reactions: Part II

  2010cites this paper
• Adverse drug reactions: Part I.

  2010cites this paper
• EDITOR'S COMMENT

  1998cites this paper